🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

2,153 results for “Ou” Clear

  1. Busulfan Koanaa 6 mg/ml Konzentrat zur Herstellung einer Infusionslösung, GRANOCYTE 34 Millions UI/ml, poudre et solvant pour solution injectable / perfusion, Autologous CD34+ cells transduced with lentiviral vector encoding the human beta-globin gene, Plerixafor Accord 20 mg/ml solution for injection

    Fondazione Telethon ETS

    transfusion-dependent beta-thalassemia

    phase 2 small molecule active

    1 trial

  2. C4531002-A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of PF-07275315 and PF-07264660 in Adult Participants with Moderate-Severe Atopic Dermatitis.

    Pfizer Australia Pty Ltd

    Moderate-Severe Atopic Dermatitis

    phase 2 other active

    1 trial

  3. C4531029:A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-group, Dose-Ranging Study to Investigate the Efficacy and Safety of PF-07275315 in Adult Participants with Inadequately Controlled Moderate-to-Severe Asthma

    Pfizer Australia Pty Ltd

    Moderate-to-severe Asthma

    phase 2 other active

    1 trial

  4. CALCIUM FOLINATE , MK-2870, -, -, PARACETAMOL , MK-1022, KEYTRUDA 25 mg/mL concentrate for solution for infusion, CALCIUM LEVOFOLINATE , CAPECITABINE , -, MK-2870, FLUOROURACIL , OXALIPLATIN

    Merck Sharp and Dohme

    Gastroesophageal cancer

    phase 2 small molecule active

    1 trial

  5. CALCIUM FOLINATE, ivonescimab, CALCIUM LEVOFOLINATE, OXALIPLATIN, FLUOROURACIL

    Ningbo Cancer Hospital

    Advanced biliary tract cancer (BTC)

    phase 2 small molecule active

    1 trial

  6. CAMPTO 20 mg/mL concentrate for solution for infusion, Futibatinib, Leucovorin-Teva 10 mg/ml Concentrate for Solution for Infusion, FLUOROURACIL, CISPLATIN, OXALIPLATIN, KEYTRUDA 25 mg/mL concentrate for solution for infusion

    Taiho Pharma Netherlands B.V.

    Solid Tumors

    phase 2 small molecule active

    1 trial

  7. CAPECITABINE , CALCIUM FOLINATE , FLUOROURACIL , DURVALUMAB , OXALIPLATIN

    Disc Medicine

    Locally advanced rectal cancer

    phase 2 small molecule active

    1 trial

  8. CAPECITABINE, Lonsurf 15 mg/6.14 mg film-coated tablets, FOLINIC ACID, FLUOROURACIL, OXALIPLATIN, NIVOLUMAB, Lonsurf 20 mg/8.19 mg film-coated tablets, LEVOLEUCOVORIN

    Ningbo Cancer Hospital

    Patients with HER 2 negative locally advanced, recurrent or metastatic gastric, oesophagus or gastroesophageal junction adenocarcinoma

    phase 2 small molecule active

    1 trial

  9. CAPECITABINE, OXALIPLATIN, FLUOROURACIL, CAPECITABINE, FOLINIC ACID

    Ningbo Cancer Hospital

    Fluoropyrimidine (FP)-naive patients with gastrointestinal (GI) cancer and available pre-treatment uracilemia ([U]) starting chemotherapy combining FP (5FU or capecitabine) and oxaliplatin for any indication

    phase 2 small molecule active

    1 trial

  10. CAPECITABINE, OXALIPLATIN, FLUOROURACIL, IRINOTECAN, CAPECITABINE

    Fondazione Telethon ETS

    Colon cancer

    phase 2 small molecule active

    1 trial

  11. CARBOPLATINE HOSPIRA 10 mg/ml, solution injectable pour perfusion, Alunbrig 30 mg film-coated tablets, Alunbrig 180 mg film-coated tablets, Pemetrexed Viatris 25 mg/ml, solution à diluer pour perfusion

    CERO THERAPEUTICS HOLDINGS, INC.

    advanced ALK-positive non-small cell lung cancer

    phase 2 small molecule active

    1 trial

  12. CASPONEB - Phase II safety lead-in randomized blind placebo controlled clinical trial : efficacy and safety of caspofungin aerosols for the curative treatment of Pneumocystis pneumonia in adjunction of conventional systemic antifungal therapy

    Tour Hekla

    Pneumocystis pneumonia

    phase 2 other active

    1 trial

  13. CBD, ABILIFY 1 mg/ml oral solution, Aripiprazolo Aurobindo 15 mg compresse, ARIPIPRAZOLE , Composition (%w/V): Sesame oil, refined 90,00, Ethanol, anhydrous 7,91, Sucralose 0,05, DL-alfa-tocopheryl acetate 0,18, Raspberry flavor 0,02.

    Fondazione Telethon ETS

    Substance-Induced Psychosis

    phase 2 small molecule active

    1 trial

  14. CEMIPLIMAB

    Fondazione Telethon ETS

    surgically resectable, high risk stage III/IV (M0) Cutaneaous Squamous Cell Carcinoma, Cutaneaous Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  15. CETUXIMAB , MK-1084, MK-1084, MK-1084, KEYTRUDA 25 mg/mL concentrate for solution for infusion., CARBOPLATIN , PEMETREXED , MK-1084

    Merck Sharp and Dohme

    Participants with KRAS G12C-Mutant, Advanced or Metastatic Nonsquamous NSCLC

    phase 2 small molecule active

    1 trial

  16. CETUXIMAB, FOLINIC ACID, FLUOROURACIL, IRINOTECAN

    Fondazione Telethon ETS

    ADCC, Colorectal Cancer

    phase 2 small molecule active

    1 trial

  17. CISPLATIN, CARBOPLATIN, KEYTRUDA 25 mg/mL concentrate for solution for infusion, CISPLATIN, FLUOROURACIL

    Takeda

    Solid Neoplasm

    phase 2 small molecule active

    1 trial

  18. CISPLATIN, Ipilimumab, PACLITAXEL, Nivolumab Subcutaneous, CARBOPLATIN, PEMETREXED

    Bristol-Myers Squibb Australia Pty Ltd

    Non-small cell lung cancer (NSCLC)

    phase 2 small molecule active

    1 trial

  19. CISPLATINE VIATRIS 25 mg/25 ml, solution à diluer pour perfusion, Tecentriq 1 200 mg concentrate for solution for infusion, CARBOPLATINE ACCORD 10 mg/ml, solution pour perfusion, Paclitaxel Accord Healthcare 6 mg/ml solution à diluer pour perfusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion, ALIMTA 500 mg powder for concentrate for solution for infusion, OPDIVO 10 mg/mL concentrate for solution for infusion.

    The George Institute

    Patients with locally advanced or metastasic Non-Small Cell Lung Carcinoma.

    phase 2 small molecule active

    1 trial

  20. CLAIRYG 50 mg/ml, solution pour perfusion, MESNA EG 100 mg/ml, solution injectable pour perfusion, CYCLOPHOSPHAMIDE SANDOZ 1000 mg, poudre pour solution injectable ou pour perfusion, SOLUMEDROL 1 g, poudre et solvant pour solution injectable

    Pari Pharma GmbH

    paraneoplastic sensory neuropathy with anti-Hu antibodies

    phase 2 small molecule active

    1 trial

  21. CM336 Injection

    The First People's Hospital of Lianyungang

    Autoimmune Bullous Disease

    phase 2 mab active

    1 trial

  22. CMP-001

    Regeneron UK Limited

    Squamous Cell Carcinoma of Head and Neck

    phase 2 small molecule terminated

    1 trial

  23. CMV-pp65 CTLs

    Evidence Based Cataract Study Group

    Cytomegalovirus

    phase 2 mab completed

    1 trial

  24. CORT125134, PACLITAXEL ALBUMIN-BOUND, BEVACIZUMAB, relacorilant

    CORCEPT THERAPEUTICS INC

    Gynecological Cancers

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources